Display Settings:

Format

Send to:

Choose Destination
    Antimicrob Agents Chemother. 2004 Nov;48(11):4271-80.

    In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up.

    Source

    Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd., Bangkok 10400, Thailand.

    Abstract

    To determine the optimum duration of follow-up for the assessment of drug efficacy against Plasmodium falciparum malaria, 96 trial arms from randomized controlled trials (RCTs) with follow-up of 28 days or longer that were conducted between 1990 and 2003 were analyzed. These trials enrolled 13,772 patients, and participating patients comprised 23% of all patients enrolled in RCTs over the past 40 years; 61 (64%) trial arms were conducted in areas where the rate of malaria transmission was low, and 58 (50%) trial arms were supported by parasite genotyping to distinguish true recrudescences from reinfections. The median overall failure rate reported was 10% (range, 0 to 47%). The widely used day 14 assessment had a sensitivity of between 0 and 37% in identifying treatment failures and had no predictive value. Assessment at day 28 had a sensitivity of 66% overall (28 to 100% in individual trials) but could be used to predict the true failure rate if either parasite genotyping was performed (r(2) = 0.94) or if the entomological inoculation rate was known. In the assessment of drug efficacy against falciparum malaria, 28 days should be the minimum period of follow-up.

    PMID:
    15504852
    [PubMed - indexed for MEDLINE]
    PMCID: PMC525402
    Free PMC Article

    Images from this publication.See all images (7) Free text

    FIG. 1.
    FIG. 6.
    FIG. 7.
    FIG. 5.
    FIG. 2.
    FIG. 3.
    FIG. 4.

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk